Prescription required. Can not be split. Product of New Zealand. Shipped from New Zealand. Synjardy is also marketed internationally under the name Jardiamet.
Prescription required. Can not be split. Product of UK/EU. Shipped from United Kingdom of Great Britain and Northern Ireland.
Prescription required. Can not be split. Product of New Zealand. Shipped from New Zealand. Synjardy is also marketed internationally under the name Jardiamet.
Prescription required. Can not be split. Product of India. Shipped from Mauritius. Synjardy is also marketed internationally under the name Jardiance Met.
Prescription required. Can not be split. Product of UK/EU. Shipped from United Kingdom of Great Britain and Northern Ireland.
Prescription required. Can not be split. Product of India. Shipped from Mauritius. Synjardy is also marketed internationally under the name Jardiance Met.
Synjardy® is a combination medication containing empagliflozin and metformin. These compounds are both used to improve blood sugar levels in adults with Type 2 diabetes. Empagliflozin is an SGLT2 inhibitor that helps remove glucose through the urine. Metformin decreases glucose production in the liver and improves insulin sensitivity.
Together, these two compounds may help manage blood sugar levels more effectively than either drug alone. It is typically prescribed along with recommendations for diet and exercise to help improve glycemic control.
To comply with Canadian International Pharmacy Association regulations you are permitted to order a 3-month supply or the closest package size available based on your personal prescription. read more
Like all prescription medications, patients and healthcare providers must consider many factors before and after starting therapy. Synjardy contains two active ingredients: metformin and empagliflozin. Each ingredient, as well as the combination, is associated with some important precautions.
Synjardy is not recommended for patients with Type 1 Diabetes.
Because both active ingredients are influenced by and can affect kidney function, assessing kidney function before and after starting Synjardy is critical.
Empagliflozin increases the amount of sugar in urine, which can increase the risk of bacterial urinary tract infections and genital fungal infections. If they occur, these infections should be treated promptly. If left untreated or they become recurrent, these infections can increase the risk of further complications.
Empagliflozin can increase the amount of urine produced, which may contribute to a higher risk of dehydration due to fluid loss. Ensure adequate fluid intake, especially in hot weather or when exercising.
Particularly when added to insulin or insulin secretagogues (e.g., sulfonylureas like glipizide or glimepiride), Synjardy can increase the risk of hypoglycemia or dangerously low blood sugars.
Metformin can influence levels of vitamin B12. Monitoring levels of vitamin B12 is recommended after starting therapy. Discuss any changes in symptoms, such as fatigue or new or worsening tingling or numbness in extremities (i.e., hands or feet).
Here are general dosage recommendations for Synjardy®:
Patient Status | Initial Dose | Maintenance Dose | Maximum Dose |
Currently on Metformin | Empagliflozin 5 mg/Metformin dose equivalent to current regimen | Adjust based on efficacy and tolerability | Empagliflozin 25 mg/Metformin 2000 mg per day |
Currently on Empagliflozin | Metformin 500 mg/Empagliflozin dose equivalent to current regimen | Adjust based on efficacy and tolerability | Empagliflozin 25 mg/Metformin 2000 mg per day |
Currently on Both Empagliflozin and Metformin | Equivalent dose of each component | Adjust based on efficacy and tolerability | Empagliflozin 25 mg/Metformin 2000 mg per day |
Renal Impairment (eGFR ≥ 45 mL/min/1.73 m²) | No dose adjustment required | Adjust based on efficacy and tolerability | Empagliflozin 25 mg/Metformin 2000 mg per day |
Renal Impairment (eGFR < 45 mL/min/1.73 m²) | Not recommended | - | - |
Dosage forms and strengths:
Formulation | Description |
5 mg empagliflozin / 500 mg metformin | Orange yellow, oval, biconvex, film-coated tablets |
5 mg empagliflozin / 1000 mg metformin | Brownish yellow, oval, biconvex, film-coated tablets |
12.5 mg empagliflozin / 500 mg metformin | Pale brownish purple, oval, biconvex, film-coated tablets |
12.5 mg empagliflozin / 1000 mg metformin | Dark brownish purple, oval, biconvex, film-coated tablets |
Here’s how to take Synjardy®:
Take medication twice daily, along with meals.
Swallow tablets whole. Synjardy tablets should not be split, crushed, dissolved, or chewed.
Gradually increase the dosage to reduce gastrointestinal side effects.
A healthcare provider must assess fluid and electrolyte balance before starting the medication.
Kidney function should be assessed before starting the medication and periodically thereafter.
Common side effects include the following:
Urinary tract infections
Genital yeast infections
Diarrhea
Nausea/vomiting
Gas or bloating
Stomach pain, upset stomach
Feeling unusually weak or tired
Headache
If you experience any of these issues, it's important to discuss them with your healthcare providers. If infections begin to recur over time, speak with your healthcare provider to determine whether it’s safe to continue the medication.
Other common questions:
Synjardy® contains two active drugs: empagliflozin (Jardiance) and metformin (Glucophage). Metformin belongs to a class called biguanides, which influence insulin production and sensitivity. Empagliflozin belongs to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors, which cause excess blood glucose to be removed in the urine.
The content on this page is for informational and educational purposes only and does not constitute professional medical advice. Patients should not use the information presented on this page for diagnosing a health-related issue or disease. Before taking any medication or supplements, patients should always consult a physician or qualified healthcare professional for medical advice or information about whether a drug is safe, appropriate or effective.